Blood Biomarkers Based Screening for HPV-driven OPC
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age50+
SponsorUNICANCER
About this trial
The objective of our study is to demonstrate that it is possible to detect and treat human papilloma virus (HPV)-related oropharyngeal cancers (OPC) early using simple blood tests. The success of this strategy will be evaluated by the number of participants positive for both HPV16-E6 serology and HPV circulating tumor DNA (ctDNA) whose early management has allowed the detection of a cancerous lesion and/or whose HPV ctDNA results have normalized after surgical intervention. If this study is conclusive, it could pave the way for the implementation of a national screening strategy for HPV-related OPC.
Eligibility criteria
Qualifiers
Aged ≥50 years from the general population
Man
No previous history of HPV-driven cancer or head neck cancer
Willingness to complete follow up visits
Disqualifiers
Aged < 50 years
Woman
History of HPV-driven cancer or head and neck cancer
Psychiatric conditions
Trial design
Treatments tested in this trial
- HPV16-E6 serology and HPV ctDNA
Treatment groups
10,000 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov